|
[Related PubMed/MEDLINE]
Total Number of Papers: 227
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI). |
DoR, ETS, mCRC, ORR, OS, PFS, TTF |
| 2 |
2020 |
A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302). |
AGC, CI, DCR, nab-PTX, OS, PFS, RR |
| 3 |
2020 |
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure. |
FN, G-CSF |
| 4 |
2020 |
Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer. |
OR |
| 5 |
2020 |
Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. |
CAFs, CI, HCC, HR, MVI, PFS |
| 6 |
2020 |
Clinical impact of controlling nutritional status score on the prognosis of patients with diffuse large B-cell lymphoma. |
CONUT, DLBCL, NCCN-IPI, OS, PFS |
| 7 |
2020 |
Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer. |
OS, PSM, RFS |
| 8 |
2020 |
Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer. |
DI, mCRPC, mCSPC, OS, PSA |
| 9 |
2020 |
Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. |
EOC, PDS |
| 10 |
2020 |
Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. |
CCI, DLBCL, EFS, OS |
| 11 |
2020 |
Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer. |
AI, LM, MBC |
| 12 |
2020 |
Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. |
AUC, CDCRI, NLR, NSCLC, PLR |
| 13 |
2020 |
Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML. |
EFS, OS |
| 14 |
2020 |
Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. |
BB, BM, CI, HR, pCR, SE, TDR |
| 15 |
2020 |
Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study. |
ADRs, CTCAE, GC, NCI, TASH |
| 16 |
2020 |
Prophylactic efficacy of ninjin'yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2). |
NYT, OS, PN, RFS |
| 17 |
2020 |
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. |
NSCLC, OS, PH |
| 18 |
2020 |
Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis. |
BCLC, mRECIST, OR, OS, uHCC |
| 19 |
2020 |
The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients. |
DFS, OS |
| 20 |
2020 |
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients. |
5'-DFUR, 5-FU, CapeOX, CES, CRC |
| 21 |
2020 |
[Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China]. |
FN, HR, ICERs, PEG-rhG-CSF, PP, QALYs, rhG-CSF, WTP |
| 22 |
2019 |
A Comprehensive Review of Methods to Measure Oral Oncolytic Dose Intensity Using Retrospective Data. |
EHR |
| 23 |
2019 |
Association between Comorbidity and Relative Dose Intensity in Patients with Diffuse Large B-Cell Lymphoma. |
DLBCL, R-CHOP |
| 24 |
2019 |
Association between Preoperative Pelvic Irradiation and Toxicity of Subsequent Chemotherapy in Rectal Cancer. |
CRC |
| 25 |
2019 |
Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer. |
BWL, DFS, OS, SMA |
| 26 |
2019 |
Chemotherapy in the oldest old: Choices and outcomes. |
--- |
| 27 |
2019 |
CYP2J2∗7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients. |
aOR, HR |
| 28 |
2019 |
Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma. |
HCC, MTA, PFS |
| 29 |
2019 |
Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. |
CI, mCRC |
| 30 |
2019 |
Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer. |
ddEC, FN |
| 31 |
2019 |
Efficacy of prolonged elemental diet therapy after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Apilot prospective randomized trial (UMIN000004108). |
CG, ED, NLR, PD, PDAC, PEDG |
| 32 |
2019 |
Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine. |
AZA, MDS, OS, OS, PFS |
| 33 |
2019 |
Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. |
OS, PFS |
| 34 |
2019 |
Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer. |
ACT, OS |
| 35 |
2019 |
Management of Thrombocytopenia in Cancer Patients. |
CIT |
| 36 |
2019 |
Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia. |
FCR, PFS |
| 37 |
2019 |
Outcome of third-line sunitinib after sequential therapy with cytokines and sorafenib in metastatic renal cell carcinoma. |
DCR, mRCC, OS, PFS |
| 38 |
2019 |
Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial. |
AC |
| 39 |
2019 |
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). |
AEs, CI, CTE, HRQoL, NCTE, ORR, OS, PFS, RCC |
| 40 |
2019 |
Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders. |
HR, STS |
| 41 |
2019 |
Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. |
OR, OS, RECIST |
| 42 |
2019 |
Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel. |
ddAC, ddP |
| 43 |
2019 |
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. |
OS, PFS |
| 44 |
2019 |
Study on the Optimal Dose of Irinotecan for Patients with Heterozygous Uridine Diphosphate-Glucuronosyltransferase 1A1 (UGT1A1). |
TTF, UGT, UGT1A1, WT |
| 45 |
2019 |
The long-term social value of granulocyte colony-stimulating factors. |
FN, G-CSF, SV |
| 46 |
2019 |
[A Case of Breast Cancer That Was Able to Accomplish Six Courses of TAC for Preoperative Chemotherapy Using Pegfilgrastim]. |
FN |
| 47 |
2019 |
[A Comparative Study on Feasibility of SOX Therapy and SP Therapy with Short Hydration for Gastric Cancer in the Outpatient Setting]. |
FN, SOX, SP-SH |
| 48 |
2018 |
Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. |
BTC, DFS, OS |
| 49 |
2018 |
Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. |
CI, HR, OS |
| 50 |
2018 |
Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6. |
5-FU, aOR, CI, PS |
| 51 |
2018 |
Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer. |
CG, NAG, NAT, PC |
| 52 |
2018 |
Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors. |
ADRs, PFS, PNET |
| 53 |
2018 |
Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma. |
RCC |
| 54 |
2018 |
Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma. |
DLTs, mRCC, OS, PFS |
| 55 |
2018 |
Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6mg support: a single-center prospective study in Japan. |
EC, G-CSF |
| 56 |
2018 |
Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative. |
IPTW |
| 57 |
2018 |
Impact of relative dose intensity on bone marrow suppression induced by S-1: retrospective observational study. |
HR |
| 58 |
2018 |
Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer. |
AGC, CI, PS |
| 59 |
2018 |
Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer. |
ESBC, G-CSF |
| 60 |
2018 |
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. |
MTA, OLLD, RP2D |
| 61 |
2018 |
Predictive factors in patients eligible for pegfilgrastim prophylaxis focusing on RDI using ordered logistic regression analysis. |
CI, OR, ROC |
| 62 |
2018 |
Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. |
OS, PFS, RR, STS |
| 63 |
2018 |
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. |
OS, PFS |
| 64 |
2018 |
Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer. |
CAPOX, DLTs, FOLFOX |
| 65 |
2018 |
The efficacy and feasibility of dose-dense sequential chemotherapy for Japanese patients with breast cancer. |
DDCT, G-CSF, pCR, TN |
| 66 |
2018 |
[Eribulin Administration Methods to Extend the Survival Time of Patients with Advanced or Recurrent Breast Cancer, Consideringthe Relative Dose Intensity, Time to Treatment Failure, Pretreatment Regimen Number, and Tumor Subtype]. |
OS, TTF |
| 67 |
2017 |
Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer. |
ADL, BC, CRP, IL |
| 68 |
2017 |
Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting. |
AIC, CIM |
| 69 |
2017 |
Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma. |
RCC |
| 70 |
2017 |
Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. |
DSAs and PSAs, FN, G-CSFs, ICERs, LY, NHL, PP, QALY, SP |
| 71 |
2017 |
Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study. |
AEs, OS, PFS |
| 72 |
2017 |
Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population. |
FNH, G-CSF, KPSC, LOS, NHL |
| 73 |
2017 |
Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. |
BSA, CIN, FN, G-CSF, PK |
| 74 |
2017 |
Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy. |
--- |
| 75 |
2017 |
Profiling chemotherapy-associated myelotoxicity among Chinese gastric cancer population receiving cytotoxic conventional regimens: epidemiological features, timing, predictors and clinical impacts. |
GEJ |
| 76 |
2017 |
Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice. |
FEC-D, G-CSF |
| 77 |
2017 |
The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer. |
CACI, OS, RFS |
| 78 |
2017 |
[Effect of Pegfilgrastim Primary Prophylactic Administration on Relative Dose Intensity(RDI)in Postoperative Adjuvant Chemotherapy(TC Therapy)for Breast Cancer - A Single-Center, Retrospective Study]. |
--- |
| 79 |
2017 |
[Efficacy and Safety of THP-COP for Diffuse Large B-Cell Lymphoma]. |
CR, DLBCL |
| 80 |
2017 |
[Treatment Out Come of Eribulin in Patients with Advanced or Metastatic Breast Cancer Who Resistant to Anthracycline and Taxane]. |
CBR, ERI, ORR, OS, PFS, PPS |
| 81 |
2016 |
Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma. |
FN, NHL |
| 82 |
2016 |
Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. |
PTX |
| 83 |
2016 |
FOLFOX chemotherapy can safely be given to neutropenic patients with early-stage colorectal cancer for higher dose intensity and fewer visits. |
5-FU, ANC, CIFN, ESCRC |
| 84 |
2016 |
Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma. |
CI, HR, mRCC, OS, TTF |
| 85 |
2016 |
Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea. |
ESBC, FN |
| 86 |
2016 |
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy. |
FN |
| 87 |
2016 |
Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer. |
ER, HER2 |
| 88 |
2016 |
Prognostic factors in patients after definitive chemoradiation using involved-field radiotherapy for esophageal cancer in a phase II study. |
CRT, EC, GTV, IFRT, OS |
| 89 |
2016 |
Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival. |
AA, ARDI, CIs |
| 90 |
2016 |
The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity. |
AC, MST, OS, PDAC, PLR |
| 91 |
2016 |
Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study. |
CI, EOC |
| 92 |
2016 |
[Analysis of the Risk Factors of Febrile Neutropenia Among 72 Women Receiving FEC in Early Breast Cancer Chemotherapy]. |
FN |
| 93 |
2016 |
[Safety and Tolerance of Dose-Dense Epirubicin and Cyclophosphamide (EC) with Pegfilgrastim for Japanese Patients with Early Breast Cancer]. |
EC |
| 94 |
2016 |
[The Clinical Utility of Pegfilgrastim in Combination with Adjuvant FEC(100)and TC Chemotherapy for Breast Cancer]. |
FN |
| 95 |
2016 |
[Use of Pegfilgrastim in Adjuvant and Neoadjuvant Chemotherapy for Breast Cancer]. |
FN |
| 96 |
2015 |
A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN. |
ANC, DI, NE |
| 97 |
2015 |
A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. |
CI, NSCLC, OS |
| 98 |
2015 |
A review of relative dose intensity and survival in patients with metastatic solid tumors. |
--- |
| 99 |
2015 |
Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. |
DFS, OS |
| 100 |
2015 |
Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey. |
DLBCL, FN, G-CSF |
|
A Search Service for Abbreviation / Long Form
